An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Latest Information Update: 22 Dec 2021
At a glance
- Drugs Ibrutinib (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms DAWN
- Sponsors Janssen Research & Development
- 04 Dec 2018 Results of the biomarker analysis assessing whether somatic mutations could be used to identify FL patients who responded to ibrutinib, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 31 May 2018 Primary endpoint (Overall response rate) has not been met, according to results published in the Journal of Clinical Oncology.
- 31 May 2018 Results (n=110) published in the Journal of Clinical Oncology.